Search Results for "Pegasys For Polycythemia Vera Side Effects"
Original Source: Pegasys® in Patients With Myeloproliferative Diseases
The goal of this clinical research study is to see if Pegasys (IFN-alpha2a) can help to control the disease in patients with essential thrombocytosis (ET), polycythemia vera (PV), agnogenic myeloid metaplasia/myelofibrosis (AMM/MF), or Philadelphia chromosome-negative chronic myeloid leukemia (Ph-negative CML). The safety of this treatment will also be studied.
Matching Channels
Verona’s lead drug, RPL554, is a dual phosphodiesterase (PDE) 3 and 4 inhibitor being developed as a novel treatment for chronic obstructive airways disease as COPD (chronic obstructive pulmon...
Kadcyla (ado-trastuzumab emtansine)
Kadcyla™ (ado-trastuzumab emtansine or T-DM1) for the treatment of people with HER2-positive metastatic breast cancer (mBC) who have received prior treatment with Herceptin® (trastuzumab)...
Although the human cytokines interleukin-2 (IL-2) and tumor necrosis factor (TNF) alpha are approved marketed for tumor therapy, their use is rather limited due to severe systemic side effects. Targ...
Matching News
Polycythemia Vera Better with Low Hematocrit
ATLANTA (MedPage Today) -- Maintaining patients with polycythemia vera at hematocrit levels below 45% reduced thrombotic complications without increasing rates of other serious adverse events.
ASH: More intense treatment beneficial in polycythemia vera
(HealthDay)—For patients with polycythemia vera, more intense treatment to achieve a hematocrit target of less than 45 percent correlates with a significantly lower rate of cardiovascular death and...
Macrophages support pathological erythropoiesis in polycythemia vera and β-thalassemia
Ramos et al. report a crucial role for macrophages in erythroblast development in mice. Under conditions that induce new red blood cell formation, macrophage depletion impaired red blood cell recovery...
Bristols-Myers Squibb filed a public knowledge-based application Nov. 26 for an additional indication of their oncology product Hydrea for treatment of essential thrombocytosis and polycythemia vera....
Lower hematocrit levels reduce cardiovascular risk in polycythemia vera
NEW YORK (Reuters Health) - Cutting hematocrit levels to below 45% can significantly reduce the risk of death or major thrombosis in patients with polycythemia vera, even compared to people whose...
AOP Orphan reports Phase II polycythemia vera data
AOP Orphan Pharmaceuticals AG (Vienna, Austria) reported data from 11 evaluable patients in the Phase II portion of the Phase I/II PEGINVERA trial of its subcutaneous AOP2014 to treat polycythemia ver...
AOP Orphan Pharmaceuticals AG (AOP Orphan) announced that based on phase II data it will initiate a phase III trial to support European Marketing Authorization of a novel mono-pegylated Interferon alp...
The EMA has expanded the approval of Pegasys...
Matching PubMed Articles
Subclones homozygous for JAK2V617F are more common and larger in patients with polycythemia vera compared to essential thrombocythemia, but their role in determining phenotype remains unclear. We geno...
Polycythemia vera: gender-related phenotypic differences.
In polycythemia vera, gender has recently been shown to influence the JAK2(V617F) allele burden, but its effect on the disease phenotype is unknown. This issue was investigated using the database of t...
Aquagenic pruritus is a symptom typical for polycythemia vera, but very little is known about its exact frequency, characteristics, influence on quality of life and proper treatment. Therefore we inve...
